This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The question is often discussed in private among patent attorneys who find themselves completely befuddled by the wanton disregard and open duplicitous handling of patentlaws by the Nation’s High Court. The whim and fancy – and intellectual dishonesty – of the Supreme Court knows no bounds when it comes to patentlaw.
In patentlaw, we also have the “ Kessler doctrine,” which sits between the two. Kessler allows for non-mutual issue preclusion even in cases where the particular issue was not actually litigated or decided. See also Mohapatra v. Hirshfeld (pro se). This typically comes in the forms of issue and claim preclusion.
Here, the Intellectual Property Litigation Group offers some of its own reactions to this decision's implications for patentlaw. Venable has offered general thoughts on the potential fallout from the Supreme Court's reversal of the long-standing Chevron deference, as well as practice area-specific analysis. By: Venable LLP
a case at the intersection of tax law and patentlaw, the Federal Circuit held that generic drug companies Hatch-Waxman litigation expenses are ordinary and necessary business expenses and can be deducted immediately. In Actavis v. By: Fenwick & West LLP
On June 1, 2021, the Fourth Amendment to the Chinese PatentLaw became effective. An important part of the amendment is the introduction by Article 76 of the patent linkage system in China – a system for litigation of drug patents prior to market entry of generics, similar to that provided by the Hatch Waxman Act in the US.
Qualcomm had previously sued Apple for patent infringement, and Apple responded with a set of inter partes review petitions. The parties settled the litigation before the IPRs were complete, but agreed that the IPRs could continue. The settlement also included a license to thousands of Qualcomm patents. 2022)(forthcoming).
Today in PatentLaw Class, we covered the Supreme Court’s important decision in Markman v. 370 (1996) focusing on the question of whether the patentee has a 7th Amendment right to have a jury decide “genuine factual disputes about the meaning of a patent?” by Dennis Crouch. Westview Instruments, Inc.,
2022 is expected to be another busy year in the world of patentlitigation. We fully expect persistence in these spaces: STANDARD-ESSENTIAL PATENT (SEP) LICENSING AND THE GROWING DEMAND FROM TECH COMPANIES FOR INDUSTRY STANDARDS - After the number of disputes involving SEPs.
Fish & Richardson is pleased to announce that the firm has been named a “Law Firm of the Year” for Litigation – Intellectual Property and Litigation – Patent in U.S. News & World Report – Best Lawyers “Best Law Firms” 2023 edition. Litigation – Intellectual Property . Litigation – Patent .
Intended to offer a thorough introduction to European IP law, the course will be covering key topics like: EU and international legal framework Trade marks and designs, including the EU design reform Geographical indications, including for handicraft products Copyright and the digital age Patentlaw, SPCs, the Unified Patent Court and patentlitigation (..)
Do defendants and the court have the right to ask who is funding a particular patentlitigation? The party must identify the third-party funder and whether the third-party funder has the right to approve litigation or settlement decisions. The issue arose as a result of two standing orders issued by Judge Connolly.
Kewalramani), the Central District of California denied Defendant Netflix’s attempts to compel Plaintiff GoTV Streaming to provide documents and further information as to the source of the litigation funding that GoTV received in conjunction with the patentlitigation.
By David Hricik, Mercer Law School I realize most readers aren’t law professors, so you can stop now… I have taught IP courses for years and often the books seek to teach the subject through cases, which is a very difficult way to learn it.
Though patents filed before the transition date will remain in force up through March 2033, a good 10+ years away, teachers may also be wondering which regime to emphasize and for how long the pre-AIA rules will still be considered fundamental rather than footnote material. 2021 Patently-O PatentLaw Journal 34.
Kilpatrick’s Alton Absher and Andie Anderson recently presented “Updates in Standard Essential Patent Licensing and Litigation” at the firm’s annual 2024 Advanced PatentLaw Seminar.
This Kat is delighted to review “ A Practitioner’s Guide to European PatentLaw: For National Practice and the Unified Patent Court ” (Hart Publishing, 2022, 664 pp.). The book consists of seventeen chapters, mainly on substantive law, but it also addresses certain procedural matters and questions of international private law.
Kilpatrick’s Alton Absher and Andie Anderson recently presented “Updates in Standard Essential Patent Licensing and Litigation” at the firm’s annual 2024 Advanced PatentLaw Seminar.
The ‘911 patent relates to “extraction of pharmaceutically active components … more particularly … botanical drug substance (B.D.S.) UCANN filed for bankruptcy in 2020, which stayed the litigation. comprising cannabinoids obtained by extraction from cannabis.” The stipulation made no mention of attorney fees.
by Dennis Crouch The Supreme Court is set to consider several significant patentlaw petitions addressing a range of issues from the application of obviousness standards, challenges to PTAB procedures, interpretation of joinder time limits IPR, to the proper scope patent eligibility doctrine. Mangrove Partners Master Fund (No.
Patent and Trademark Office (PTO) are constantly reshaping patentlaw, and this program will teach you everything you need to know about the basics of patentlitigation in this dynamic, rapidly changing landscape. Whether you’re a novice or experienced patentlitigator, By: Practising Law Institute (PLI)
Applicants, for their part, are not required to disclose prior art that is not material to patentability or that is cumulative of other prior art they’ve already provided. It may surprise you, then, to learn that the genre of science fiction is deeply indebted to patentlaw and patent theory. See [link].
Among the most established standards in patentlaw is that obviousness requires a motivation to combine the prior art with “a reasonable expectation of success.” The Federal Circuit alone has employed the “reasonable expectation” formulation in hundreds of opinions spanning the past four decades.
Kilpatrick’s Steve Borgman and Andrew Saul recently presented at the 29th Annual Advanced PatentLaw Institute in Austin, Texas, on recent cases and trends in the courts and the USPTO involving Section 101, as well as some of the highlights (or lowlights) in the 10 years since Alice. By: Kilpatrick
Though patents filed before the transition date will remain in force up through March 2033, a good 10+ years away, teachers may also be wondering which regime to emphasize and for how long the pre-AIA rules will still be considered fundamental rather than footnote material. 2021 Patently-O PatentLaw Journal 34.
With expansive new federal legislation targeting PBMs, Medicare proceeding apace in negotiating drug prices, ongoing litigation over access to mifepristone and other women’s healthcare, and expansion of DOJ enforcement interest in digital health, the health care industry continues to change dramatically.
few non-patent IP cases pending before the Supreme Court of some interest: Unicolors, Inc. 20-915 (referral of copyright litigation issues to copyright office) (this is the only one granted certiorari, oral arguments set for November 8, 2021); Ezaki Glico Kabushiki Kaisha v. . = = =. A H&M Hennes & Mauritz, L.P. ,
Litigation funders often see the attorneys they would be working with as the most important element of whether to invest in a case, several members of the industry said on a panel at the University of Texas School of Law's Advanced PatentLaw Institute.
Sources say updates to the Chinese PatentLaw regarding design patents are likely to bring in a wave of new filings, and a surge in litigation along with it
Even if you are not a litigator, you may still remember learning about the R.26(a)(1) Some areas of law have particular additional disclosure requirements. One example — old patentlaw. by Dennis Crouch. 26(a)(1) initial disclosures required at the start of a lawsuit.
The Pharma Letter asked Ms Del Dotto, an intellectual property and life sciences litigation attorney, for an overview of changes made under the recent Orange Book Transparency Act, as well as an insight into potential exclusivity changes under consideration by the U.S.
As a result, the Federal Circuit was not persuaded the “venue ruling implicates a ‘basic, unsettled, recurring legal issue [] over which there is considerable litigation producing disparate results,’ or similar circumstances that might warrant mandamus.”
Litigation surrounding the three-year market exclusivity provision shows us not only how inherently ambiguous the provision is but also the need for a clearly defined standard. Here, patentlaw can be very helpful in determining whether a generic manufacturer satisfies the novelty, usefulness, and non-obviousness standards.
patents despite the fact that the traditional basis for ODP doctrine no longer exists under U.S. patentlaw. The NYIPLA’s brief contends that the Federal Circuit’s decision increases the risk of invalidity for a significant portion of U.S.
Specifically, this case discusses whether a party’s waiver of a doctrine-of-equivalents theory in an initial lawsuit extends to a subsequent case involving a newer iteration of the technology previously litigated. By: Sheppard Mullin Richter & Hampton LLP
The most recent chapter ended with the district court finding the Sonos patents at issue in their patentlitigation against Google were unenforceable due to laches because Sonos had the audacity to file a continuation and seek claims supported by—and actually incorporated from—an earlier filing.
By the time the district court reaches final judgment any harm due to litigating in an inconvenient forum is typically water-under-the-bridge leaving no cognizable harm for the appeal. An oddity of patentlitigation jurisprudence is that Section 1404 determinations are not deemed patent-law specific.
In its place, the Federal Circuit emphasized a flexible approach to the design patent obviousness analysis, grounded in the Graham factors.1 1 This is a big change in design patentlaw. By: Sterne, Kessler, Goldstein & Fox P.L.L.C.
The past several years have brought a dizzying array of changes in patentlaw, between proposed new legislation, new USPTO filing procedures, and Supreme Court activity at a rate not seen in decades. By: Practising Law Institute (PLI)
Moderna and Pfizer battle’s over the inventive process of their respective mRNA COVID-19 vaccines revisit the negative associations of profit, monopolies, and optics in patentlitigation. This exposes some concerns about our patentlaws.
Patent and Trademark Office (PTO) are constantly reshaping patentlaw, and this program will teach you everything you need to know about the basics of patentlitigation in this dynamic, rapidly changing landscape. Whether you’re a novice or experienced patentlitigator, By: Practising Law Institute (PLI)
Director Review at the Patent Trial and Appeal Board (PTAB) remains a hot topic in patentlaw. The Director first established an interim process for Director Review in the wake of the Supreme Court’s 2021 decision in United States v.
In the Hatch-Waxman arena of patentlitigation, the crisscross of patentlaws and FDA regulations is always in play. 24, 2023), we see another iteration of this with respect to listing a method-of-use patent in the Orange Book. In the recent Federal Circuit decision in Jazz Pharmaceuticals, Inc.
Last Friday, WIPO published An International Guide to Patent Case Management for Judges. For each jurisdiction, there are several chapters which sets out the procedure and practice for managing patent cases, namely patent infringement cases., while also " integrating pertinent patentlaw doctrines ".
In the Western District of Texas, this 100% assignment occurs in the Midland-Odessa division (assigned to Judge David Counts), the Pecos Division (also Judge Counts), the Del Rio Division (Judge Alia Moses), and—most importantly for patentlaw—the Waco Division (Judge Alan Albright).
We organize all of the trending information in your field so you don't have to. Join 9,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content